293 reports of this reaction
5.2% of all CARVEDILOL PHOSPHATE reports
#2 most reported adverse reaction
FATIGUE is the #2 most commonly reported adverse reaction for CARVEDILOL PHOSPHATE, manufactured by Waylis Therapeutics LLC. There are 293 FDA adverse event reports linking CARVEDILOL PHOSPHATE to FATIGUE. This represents approximately 5.2% of all 5,587 adverse event reports for this drug.
Patients taking CARVEDILOL PHOSPHATE who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among CARVEDILOL PHOSPHATE users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for CARVEDILOL PHOSPHATE:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 293 FDA reports for CARVEDILOL PHOSPHATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 5.2% of all adverse event reports for CARVEDILOL PHOSPHATE, making it one of the most commonly reported side effect.
If you experience fatigue while taking CARVEDILOL PHOSPHATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.